BioPortfolio - CP-945598
CP-945598 is a selective antagonist of the cannabinoid type 1 (CB1). .... The CB1 receptor antagonists, of which there are three in development, CP945598, ...
http://www.bioportfolio.com/search/CP-945,598.html...
|
BioPortfolio - CP-945598 RAT
Additional CB1 antagonists in the pipeline include CP-945598 (otenabant) and ... .. V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in . ...
http://www.bioportfolio.com/search/CP-945598_RAT.html...
|
Novel anorectic strategies
On the other hand, the CB1 antagonist, SR141716 (0.3-3mg/kg) was found to reduce sucrose intake in rats although overall chow intake was only marginally ...
http://www.bioportfolio.com/LeadDiscovery/0449.htm...
|
BioPortfolio - Vagotomy research
The selective CB1 receptor antagonist rimonabant is a novel weight control... Direct Link, 16th October, 2008, Department of Surgery, Division of Esophagus
...
http://www.bioportfolio.com/indepth/Vagotomy/research.html...
|
BioPortfolio - Seed Biotechnology Centi - Profile
Non-Brain Penetrant CB1 Antagonists from Jenrin Discovery Show Beneficial Effects in Treating. 1/3. Page 2. Diabetes and Obe. Pharmacy Choice: Oct 31 2008
...
http://www.bioportfolio.com/biocorporate/9313-Seed+Biotechno...
|
BioPortfolio - Green Cross - Profile
Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB(1) receptor antagonists. Since the CB1 receptor antagonist SR141716 (rimonabant)
...
http://www.bioportfolio.com/biocorporate/23691-Green+Cross.p...
|
Innovations in The Management of Diabetes - Next generation ...
Sanofi-Aventis’ Acomplia (rimonabant) is a first-in-class CB-1 antagonist indicated for the treatment of overweight patients with associated Type 2
diabetes ...
http://www.bioportfolio.com/cgi-bin/acatalog/Innovations_in_...
|
LeadDiscovery - Therapeutic Advances - Focus on Cardiovascular Disease
CB1 antagonists reduce survival rates following experimental myocardial infarction · Ezetimibe prevents the development of artherosclerosis ...
http://www.bioportfolio.com/LeadDiscovery/targetcardiovascul...
|
BioPortfolio - Aventis
Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in ... Recent Search Terms used to find this page: CB1
antagonist | . ...
http://www.bioportfolio.com/biocorporate/1110-Aventis.html...
|
Addiction Medicine Update
... Opioid antagonist; Mechanism of action in alcoholism is not understood ... Smoking/ nicotine dependence, CB1 (endocannabinoid) receptor antagonist ...
http://www.bioportfolio.com/reports/DMD_Addiction%20Medicine...
|
CB1 antagonist reverses hypotension in cirrhotic rats
827-32, 2001 of Nature Medicine CB1 antagonist reverses hypotension in cirrhotic rats. Using an automated tail-cuff device, we monitored daily the systolic ...
http://www.niaaa.nih.gov/ResearchInformation/IntramuralResea...
|
British Journal of Pharmacology - CB1 receptor antagonist ...
CB1 receptor antagonist SR141716A increases capsaicin-evoked release of Substance P .... CB1 antagonist SR141716A modulates capsaicin-evoked SP-LI
release ...
http://www.nature.com/bjp/journal/v135/n1/full/0704506a.html...
|
Reduction of opioid dependence by the CB1 antagonist SR141716A in ...
Reduction of opioid dependence by the CB1 antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=15...
|
British Journal of Pharmacology - Reduction of opioid dependence ...
Reduction of opioid dependence by the CB1 antagonist SR141716A in mice: evaluation of ... In contrast, an acute injection of the CB1 antagonist just
before ...
http://www.nature.com/bjp/journal/v132/n8/full/0703990a.html...
|
Oral bioavailability of the novel cannabinoid CB1 antagonist ...
The present studies compared the effects of AM4113 and a novel CB1 antagonist, AM6527, on the suppression of food-reinforced behavior following ...
http://www.ncbi.nlm.nih.gov/pubmed/18703081...
|
Neuropsychopharmacology - Attenuation of Cue-Induced Heroin ...
Attenuation of Cue-Induced Heroin-Seeking Behavior by Cannabinoid CB1 Antagonist Infusions into the Nucleus Accumbens Core and Prefrontal Cortex, ...
http://www.nature.com/npp/journal/v33/n10/full/1301630a.html...
|
Rimonabant--a selective CB1 antagonist. [Ann Pharmacother. 2005 ...
CONCLUSIONS: Rimonabant appears to be a promising drug in an entirely new class called selective cannabinoid CB1 receptor antagonists. ...
http://www.ncbi.nlm.nih.gov/pubmed/15755787...
|
CB1 cannabinoid receptor antagonism: a new strategy for the ...
CB1 receptors were highly induced in human cirrhotic samples and in liver fibrogenic cells. Treatment with the CB1 receptor antagonist SR141716A decreased
...
http://www.nature.com/nm/journal/v12/n6/full/nm1421.html...
|
Peripheral, but not central, CB1 antagonism provides food intake ...
Peripheral treatment with CB1 antagonist (Rimonabant) also reduced food intake and body weight but, in addition, independently triggered lipid mobilization ...
http://www.ncbi.nlm.nih.gov/pubmed/18716045...
|
CB1 receptor antagonist SR141716A increases capsaicin-evoked ...
Capsaicin induced SP-LI release is increased by CB1 antagonist SR141716A. Data represent mean±s.e.mean SP-LI release from mouse cords evoked by capsaicin ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=15...
|
